- Home
- GNS vs CUE Comparison
GNS vs CUE Comparison
Compare GNS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | CUE |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.1M | 27.8M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GNS | CUE |
|---|---|---|
| Price | $0.34 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 772.4K | 762.9K |
| Earning Date | 03-09-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | $220.56 | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.21 | $0.23 |
| 52 Week High | $1.92 | $1.05 |
Technical Indicators
Market Signals| Indicator | GNS | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 38.07 |
| Support Level | $0.30 | $0.23 |
| Resistance Level | $0.48 | $0.35 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 0.86 | 18.42 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.